Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 3/20 | 0.53 |
| ▸ | TLR2 | O60603 | 2/20 | 0.51 |
| ▸ | MDM4 | O15151 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 7/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23728661 | 1.00 | MDM2 (0.53) | MDM2TLR2MDM4TP53PTPN1 | |
| SCHEMBL30523139 | 1.00 | MDM2 (0.53) | MDM2TLR2MDM4TP53PTPN1 | |
| SCHEMBL23728660 | 1.00 | MDM2 (0.53) | MDM2TLR2MDM4TP53PTPN1 | |
| SCHEMBL12658044 | 0.97 | PTPN1 (0.53) | MDM2TLR2MDM4TP53PTPN1 | |
| SCHEMBL30523140 | 0.97 | PTPN1 (0.53) | MDM2TLR2MDM4TP53PTPN1 | |
| SCHEMBL22373690 | 0.96 | MDM2 (0.54) | MDM2TLR2MDM4TP53PTPN1 | |
| SCHEMBL120511 | 0.96 | MDM2 (0.55) | MDM2TLR2MDM4TP53 | |
| SCHEMBL29792120 | 0.96 | MDM2 (0.55) | MDM2TLR2MDM4TP53 | |
| SCHEMBL117964 | 0.96 | MDM2 (0.55) | MDM2TLR2MDM4TP53 | |
| SCHEMBL29768913 | 0.96 | MDM2 (0.55) | MDM2TLR2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11485792-B2 | Antibodies, uses thereof and conjugates thereof | POLYTHERICS LIMITED | 2022-11-01 | — | — | US | disclosed |
| EP-3218009-B1 | PROCESS FOR THE CONJUGATION OF A PEPTIDE OR PROTEIN WITH A REAGENT COMPRISING A LEAVING GROUP INCLUDING A PORTION OF PEG | POLYTHERICS LTD (GB) | 2021-04-07 | — | — | EP | disclosed |
| US-10835616-B2 | Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of PEG | POLYTHERICS LIMITED (GB) | 2020-11-17 | — | — | US | disclosed |
| US-20200268885-A1 | Conjugates And Conjugating Reagents | POLYTHERICS LIMITED (GB) | 2020-08-27 | — | — | US | disclosed |
| US-20190144562-A1 | ANTIBODIES, USES THEREOF AND CONJUGATES THEREOF | ABZENA (UK) LIMITED (GB) | 2019-05-16 | — | — | US | disclosed |
| US-20170304461-A1 | Process For The Conjugation Of A Peptide Or Protein With A Reagent Comprising A Leaving Group Including A Portion Of PEG | POLYTHERICS LIMITED (GB) | 2017-10-26 | — | — | US | disclosed |
| US-20170290925-A1 | Conjugates And Conjugating Reagents | POLYTHERICS LIMITED (GB) | 2017-10-12 | — | — | US | disclosed |
| WO-2016059377-A1 | PROCESS FOR THE CONJUGATION OF A PEPTIDE OR PROTEIN WITH A REAGENT COMPRISING A LEAVING GROUP INCLUDING A PORTION OF PEG | POLYTHERICS LIMITED (GB) | 2016-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304461-A1 | Process For The Conjugation Of A Peptide Or Protein With A Reagent Comprising A Leaving Group Including A Portion Of PEG | LNPEP, ANPEP, NGLY1 | MDM2 1134/4885TLR2 3204/4885MDM4 3420/4885 |
| US-20170290925-A1 | Conjugates And Conjugating Reagents | ANPEP, NGLY1, PCTP | MDM2 2441/4885TLR2 3035/4885MDM4 3611/4885 |
| US-20200268885-A1 | Conjugates And Conjugating Reagents | ANPEP, NGLY1, PCTP | MDM2 2441/4885TLR2 3035/4885MDM4 3611/4885 |
| US-10835616-B2 | Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of PEG | LNPEP, ANPEP, NGLY1 | MDM2 1134/4885TLR2 3204/4885MDM4 3420/4885 |
| US-20190144562-A1 | ANTIBODIES, USES THEREOF AND CONJUGATES THEREOF | KLK3, VSIG8, IGLV6-57 | MDM2 3215/4885TLR2 3436/4885MDM4 1079/4885 |
| US-11485792-B2 | Antibodies, uses thereof and conjugates thereof | KLK3, VSIG8, IGLV6-57 | MDM2 3215/4885TLR2 3436/4885MDM4 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.